Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine

6 Dec 2024

Abstract excerpt

BACKGROUND: BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) encode for tumor suppressor proteins which are critical regulators of the Homologous Recombination (HR) pathway, the most precise and important DNA damage response mechanism. Dysfunctional HR proteins cannot repair double-stranded DNA breaks in mammalian cells, a situation called HR deficiency. Since their identification, pathogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Epigenetics and DNA Methylation
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39643918
DOI: 10.1186/s13148-024-01787-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicinePMID 39643918Read ↗

<em>BRAC1</em> & <em>BRCA2</em> Methylation as a Prognostic and Predictive Biomarker in Cancer: Implementation in Liquid Biopsy in the Era of Precision MedicineSemantic proximity Read ↗

DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?Semantic proximity Read ↗

DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer TypesSemantic proximity Read ↗

Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.Semantic proximity Read ↗

Νovel methylation biomarkers in liquid biopsy and classifying biosignatures for the clinical management of Breast CancerSemantic proximity Read ↗

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast CancerSemantic proximity Read ↗

Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine eraSemantic proximity Read ↗

Use of DNA methylation for cancer detection: promises and challenges.Semantic proximity Read ↗

Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.Semantic proximity Read ↗

Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient TumorsSemantic proximity Read ↗

Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-ProficientSemantic proximity Read ↗

Establishment of a RESEARCH USE ONLY Condensed-Efficient-Fast (CEF) PITX2 workflow for analysis of PITX2 DNA methylation in small tumor tissue samples Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.